A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis*1

Evaluation of 308‐nm monochromatic excimer light in the treatment of psoriasis vulgaris and palmoplantar psoriasis

“…Our findings, although significant, were not as impressive as those observed in the psoriasis vulgaris group (75% vs 53% reduction). Carlin et al (16) have suggested that a PASI score reduction of 50% can be considered a clinically significant endpoint in the assessment of psoriasis. We chose to treat this group less intensively with a once weekly dosing regimen in order to evaluate whether this schedule was effective, as this schedule provides the greatest convenience to the patient and increases therapy compliance.…”